复星医药(02196.HK)子公司产品抽检不合格
复星医药(02196.HK)公布,中国药监局发布《国家药监局关於83批次药品不符合规定的通告(2019年第75号)》,经辽宁省药品检验检测院抽检,控股子公司苏州二叶生产的一批次产品不符合规定。公司表示,有关产品於2018年度及2019年上半年的销售收入分别约为7,000万元人民币(下同)及6,200万元,分别占同期营业收入之0.3%及0.4%,对公司之正常生产经营未造成实质性影响。
公司并指,管理层对此高度重视,已要求苏州二叶就产品生产过程进行全面覆查并及时完成整改,并督促各成员企业以此次事件为诫,进一步加强药品生产质量的全过程管理,持续提升产品全生命周期的质量风险管理水平,防止此类情况再次发生,又指苏州二叶已根据苏州市市场监督管理局的要求完成整改。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.